It is well established that patients affected by GCK-MODY do not require any pharmacological treatment [15], while patients with HNF1A or HNF4A-MODY have a good response to sulfonylureas in term of glycaemic control and prevention of micro- and macrovascular complications [24]. The gene discussed is HNF1A; the disease is MODY.